ClinicalTrials.gg
CompletedNCT06948292QRX-3 in CKDUpdated Sep 8, 2025

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

A Phase 2 interventional study of QRX-3 in Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease and Hypertensive Kidney Disease, sponsored by Ebima Clifford Okundaye. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Ebima Clifford Okundaye · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 2 months ago, and no results have been posted to the registry.
  • Registered 2 years 1 month after the study started (first participant enrolled Mar 2023, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.

Enrollment
44th of 120
127 · median 79
Started
2023
with 6 others
Phase 2
54 of 153
5 open now
Registered
146th of 153
by date

Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 44th largest by enrollment of the 120 interventional ones that give a count, is one of 7 that started in 2023, is one of 54 in phase 2, and was the 146th registered.

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Diabetic Nephropathies with a site in United States, or all of them as a file.
02

Study summary

QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal tubular injury and restoration of optimized renal function above baseline , will be studied in patients with progressive chronic kidney disease over 12 months . The result of the change in renal function expressed as creatinine GFR (Glomerular filtration decline) over the treatment duration will be compared in the treatment group will be compared to control group without the medication during that same period .

03

Conditions studied

  • Chronic Kidney Disease Stages 3-5
  • Diabetic Kidney Disease
  • Hypertensive Kidney Disease

Keywords

  • CKD
  • estimated GFR (eGFR)
  • proteinuria
  • random urine protein creatinine ratio
  • creatinine change
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with Chronic kidney disease stage 3-5
  • Estimated Glomerular function by of less than 60mls/min
  • Patients with declining renal function ( as measured by eGFR by MDRD )
  • Rate of decline of eGFR over the last one year of less than 20%
  • Negative Serology markers for CKD etiology
  • Provider perceived adherence to study follow- up

Exclusion criteria

Exclusion Criteria:

  • Rapid rate of decline in kidney function of > 10 % over 3 months
  • Symptomatic renal failure
  • Presence of any suspected Acute renal failure superimposed
  • Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI
  • No known reversible cause of renal decline
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
127 participants (actual)

Study arms

  • No intervention
    control group

    control group - continued on standard therapy for CKD

  • Active comparator
    Intervention group

    QRX-3 drug given in addition to standard therapy for CKD

    Drug: QRX-3

Interventions

  • DrugQRX-3

    phase 2B CKD study

06

What researchers measure

Primary outcomes

  1. daily change in glomerular filtration rate by creatinine in mls/min

    mean change in glomerular filtration rate by creatinine in mls/min in one year compare to baseline at screening

    Time frame: 12 months

Secondary outcomes

  1. change in proteinuria by mg/g

    change in mean proteinuria measured by random urine protein/creatinine ratio at 12 months compare to control will be compared in both groups

    Time frame: 12 months

07

Study locations

1 site
  • Neukidney Inc
    Pasedena, Texas 77504, United States
08

References and documents

Individual participant data

Plan to share: Yes — if requested , deidentifiable data can be shared

Supporting information: Clinical study report

Time frame: 4/21/2025 to 10/21/2025

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Aug 2024, 17 months.

Of 32 industry-sponsored phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 17 months is below that.

Counting every sponsor, half of 52 studies reached it within 21 months; a quarter within 13 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2025
First posted
Apr 29, 2025
StartActual
Mar 1, 2023
Primary completionActual
Aug 30, 2024
CompletionActual
Oct 30, 2024
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06948292
Lead sponsor
Ebima Clifford Okundaye
Responsible party
Ebima Clifford Okundaye (Principal investigator, Neukidney Inc.) — Sponsor-investigator
First posted
Apr 29, 2025
Start date
Mar 1, 2023
Primary completion
Aug 30, 2024
Completion
Oct 30, 2024
Last update
Sep 8, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion